2010
News
November 8, 2010: Allan B.
Haberman, Ph.D. was quoted in an article entitled “Bristol-Myers Squibb reaps
biologics in ZymoGenetics windfall”, in the November 2010 issue of Nature
Biotechnology. The article focused on the acquisition of ZymoGenetics (Seattle,
WA) by Bristol-Myers Squibb (BMS), with a special focus on ZymoGenetics' hepatitis
C drug pegylated interferon-lambda.
To read
the article, go to http://www.nature.com/nbt/journal/v28/n11/full/nbt1110-1137.html
(subscription required).
November 4,
2010: Cambridge Healthtech Institute (CHI) announced the publication of a
new book-length report, RNAi
Therapeutics: Second Generation Candidates Build Momentum, by Allan B. Haberman,
Ph.D. This new Insight Pharma Report examines the science behind therapeutic RNAi
(RNA interference) and miRNA (microRNA), technologies for design of therapeutic
oligonucleotides that work via an RNAi or miRNA-modulating mechanism, technologies
for design of delivery vehicles, and leading specialty companies in the therapeutic
RNAi/miRNA industry sector.
The report also
includes a discussion of the outlook for the therapeutic RNAi/miRNA industry sector,
including strategic issues such as technological prematurity and the development
of enabling technologies, the role of Big Pharma investment, and the impact of
patent litigation and cross-licensing in shaping the RNAi/miRNA sector. It also
includes a scenario for the development of RNAi and miRNA-based drugs. Also included
are transcripts of interviews with five leaders of biotech companies in the RNAi/miRNA
industry sector.
For more information on the
report, or to order it, see the CHI
Insight Pharma Reports website.
June
4, 2010: Haberman Associates’ Biopharmconsortium Blog, formerly at http://biopharmconsortium.blogspot.com,
has moved to our own site. You can now find it at http://biopharmconsortium.com/blog.
We
started the Biopharmconsortium Blog in July of 2009. The blog contains expert
commentary on recent life science industry news and recent published scientific
reports and business articles.
We hope that
you will continue to visit and subscribe to our blog in its new location. We also
welcome comments and discussions of our blog articles from people in the life
science community, including companies, academic institutions, and disease organizations
and patient advocates.
March 16, 2010:
“Reducing
Attrition In Silico” by Allan B. Haberman, Ph.D. was published in the
March-April 2010 issue of Bio-IT World. This article is based on an excerpt
from Chapter 8 of the recently published book-length report Animal Models for
Therapeutic Strategies.
March 5, 2010:
Cambridge Healthtech Institute (CHI) announced the publication of a new book-length
report, Animal Models for Therapeutic Strategies, by Allan B.
Haberman, Ph.D. This new Insight Pharma Report discusses the use of animal
models to develop new paradigms for drug discovery and development in important
human diseases. The report also discusses strategies for developing more predictive
models of drug efficacy. Poorly predictive animal models are a major reason for
Phase II and Phase III pipeline drug attrition. Thus this new report complements
our May 2009 Insight Pharma Report, Approaches
to Reducing Phase II Attrition.
For more information on the
report, or to order it, see the CHI
Insight Pharma Reports website.
